Context: There are no reports in the literature of massive deep venous thrombosis (DVT) associated with cisplatin, bleomycin and etoposide (BEP) cancer treatment.
Case Report: The patient was a 18-year-old adolescent with a nonseminomatous germ cell tumor of the right testicle, with the presence of pulmonary, liver, and massive retroperitoneal metastases. Following radical orchiectomy, the patient started chemotherapy according to the BEP protocol (without routine prophylaxis for DVT). On day 4 of the first cycle, massive DVT was diagnosed, extending from both popliteal veins up to the thoracic segment of the inferior vena cava. Thrombolytic therapy with streptokinase was immediately started. On day 2 of thrombolytic therapy, the patient developed acute renal failure, due to extension of the thrombosis to the renal veins. Streptokinase was continued for six days and the outcome was remarkably favorable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11068282 | PMC |
| http://dx.doi.org/10.1590/s1516-31802006000600009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-induced thrombotic microangiopathy after adjuvant chemotherapy in malignant ovarian germ cell tumor: A case report and literature review.
Taiwan J Obstet Gynecol
November 2024
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei City, Taiwan; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei City, Taiwan. Electronic address:
Article Synopsis
- - A rare case of drug-induced thrombotic microangiopathy (DI-TMA) occurred in a 21-year-old woman after receiving BEP chemotherapy for a malignant ovarian germ cell tumor.
- - The patient initially had a pelvic mass diagnosed as an endodermal sinus tumor and developed symptoms like anemia and kidney injury after chemotherapy, leading to a DI-TMA diagnosis.
- - Following treatment with plasma exchange and discontinuation of chemotherapy, the patient remained disease-free for 17 months, highlighting the need for quick diagnosis and treatment of DI-TMA associated with chemotherapy.
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
J Clin Oncol
October 2024
Department of Cancer Medicine, Hôpital Saint Louis, Paris, France.
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy and toxicity. Two hundred and sixty-three patients with International Germ Cell Cancer Consensus Group poor prognosis received one cycle of bleomycin, etoposide, and cisplatin (BEP): 51 with a favorable tumor marker decline continued with three cycles of BEP (Fav-BEP) and 203 with an unfavorable decline were randomly treated with three BEP (Unfav-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of paclitaxel-BEP-oxaliplatin + two cycles of cisplatin, ifosfamide, and bleomycin).
View Article and Find Full Text PDFOvarian Yolk Sac Tumors: Is Fertility Preservation Possible?
Adv Biomed Res
January 2024
Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Yolk sac tumors make up 14% to 20% of all malignant ovarian germ cell tumors. Serum alpha-fetoprotein (AFP) levels are elevated in a significant number of patients and are useful for monitoring the response to treatment and for post-treatment surveillance. Surgery is required for diagnosis, staging, and treatment.
View Article and Find Full Text PDFTesticular Germ Cell Tumors in Children and Adolescents Treated With Bleomycin, Etoposide, and Cisplatin (BEP) Protocol: A Survival Analysis.
Cureus
November 2023
Pediatric Oncology, Instituto Nacional de Cancerología, Bogotá, COL.
Background: Germ cell tumors (GCTs) represent a diverse group of rare neoplasms that vary in location, histology, and clinical presentation. This study focuses on the clinical outcomes and survival rates of children and adolescents treated with the bleomycin, etoposide, and cisplatin (BEP) protocol.
Methods: This observational study evaluated children under 18 years diagnosed with testicular germ cell tumors and treated with the BEP protocol from January 2008 to December 2018.
Ovarian steroid cell tumors are a rare subtype of sex-cord stromal cell tumors. Overall, these tumors make <0.1% of all ovarian tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!